Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics, Inc. (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
$15.97
$0.42(2.22%)
At close: 4:00 PM EST
$15.97
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.18 - $22.50
Previous CloseN/A
Volume302.00K
Average Volume (3M)932.72K
Market Cap
$1.64B
Enterprise Value$1.19B
Total Cash (Recent Filing)$592.94M
Total Debt (Recent Filing)$55.73M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Apr 14, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding102,843,010
10 Day Avg. Volume779,086
30 Day Avg. Volume932,722
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue14.20
Enterprise Value/Gross Profit-16.25
Enterprise Value/Ebitda-4.64
Forecast
1Y Price Target
$31.83Price Target Upside99.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.13
Revenue Forecast (FY)$57.76M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityDurable and deepening responses in heavily pretreated chronic lymphocytic leukemia patients, paired with a favorable tolerability profile versus competitors, support the drug's potential to capture late-line market share.
Partnerships And Pipeline OptionalityA Sanofi-partnered STAT6 degrader and other partnered programs advancing toward clinical testing broaden growth pathways beyond the lead asset and create potential milestone and co-promotion value.
Regulatory Pathway And Pivotal TrialAdvancement into a confirmatory head-to-head pivotal study and an accelerated approval strategy for the lead oral degrader could align with regulators and increase the prospect of earlier market access.
Bears Say
Clinical Execution Risk And VolatilityDependence on multiple pivotal trials and sequential data readouts makes stock performance vulnerable to sharp swings driven by binary clinical outcomes.
Competitive Program RiskEmergence of rival STAT6 and other competitive degradation programs could reduce differentiation and limit potential market penetration for the company's assets.
Regulatory Approval And Commercial Uptake RiskFailure to obtain regulatory approvals or achieve expected patient uptake would materially weaken commercial prospects and downside the valuation.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics, Inc.’s price range in the past 12 months?
Nurix Therapeutics, Inc. lowest stock price was $8.18 and its highest was $22.50 in the past 12 months.
What is Nurix Therapeutics, Inc.’s market cap?
Nurix Therapeutics, Inc.’s market cap is $1.64B.
When is Nurix Therapeutics, Inc.’s upcoming earnings report date?
Nurix Therapeutics, Inc.’s upcoming earnings report date is Apr 14, 2026 which is in 43 days.
How were Nurix Therapeutics, Inc.’s earnings last quarter?
Nurix Therapeutics, Inc. released its earnings results on Jan 28, 2026. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.871 by $0.051.
Is Nurix Therapeutics, Inc. overvalued?
According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued.
Does Nurix Therapeutics, Inc. pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
What is Nurix Therapeutics, Inc.’s EPS estimate?
Nurix Therapeutics, Inc.’s EPS estimate is -0.76.
How many shares outstanding does Nurix Therapeutics, Inc. have?
Nurix Therapeutics, Inc. has 102,843,010 shares outstanding.
What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?
Nurix Therapeutics, Inc. reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.871. Following the earnings report the stock price went down -1.567%.
Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.83 (99.31% Upside)
$31.83 (99.31% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.46%
12-Months-Change
Fundamentals
Return on Equity
-49.63%
Trailing 12-Months
Asset Growth
4.02%
Trailing 12-Months
Company Description
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
NRIX Stock 12 Month Forecast
Average Price Target
$31.83
▲(99.31% Upside)
Technical Analysis
Arvinas Holding Company
―
Vir Biotechnology
―
Relay Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
0.21% Insiders
11.92% Mutual Funds
20.33% Other Institutional Investors
46.31% Public Companies and
Individual Investors